This article deals with trainees’ decision-making of treatment for psychosis using cross-sectional, semi-structured questionnaire-based study of the 726 respondents. Trainees are more likely to choose second-generation antipsychotic medication for patients and themselves.
Despite being aware of evidence that suggests otherwise, they predominantly base these choices on perceived efficacy.